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in Patients with Cardiac Persistence of Human
Parvovirus B19 Infection
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Heinz-Peter Schultheiss,1 and Carsten Tschöpe1,2
1Department of Cardiology and Pneumology, Charité–University Medicine Berlin, Campus Benjamin Franklin, and 2Berlin-Brandenburg Center of
Regenerative Medicine, Berlin, and 3Department of Molecular Pathology, University Hospital of Tübingen, Tübingen, Germany
Background. In a phase 1 study, we investigated whether interferon beta reduced endothelial damage in patients
with cardiac persistence of human parvovirus B19 (B19V) infection.
Methods and results. In vitro, B19V infected cultivated endothelial cells (ECs), which led to a reduction in
their viability ( ). Interferon beta suppressed B19V replication by 63% ( ) in ECs and increasedP p .007 P p .008
their viability ( ). Circulating mature apoptotic ECs (CMAECs [CD45CD146+ cells expressing von Wil-P p .021
lebrand factor and annexin V]) and circulating progenitor cells (CPCs [CD34+KDR+ cells]) were quantified by
flow cytometry in 9 symptomatic patients with cardiac B19V infection before and after 6 months of interferon
beta therapy (16 MU) and were compared to levels in 9 healthy control subjects. Endothelial dysfunction was
measured using flow-mediated dilatation of the forearm. Patients with B19V persistence had significantly higher
( ) levels of CMAECs than did control subjects, which normalized after treatment (mean  standardP p .004
deviation, vs ; ). Similar improvement was shown for flow-mediated0.06%  0.08% 0.01%  0.006% P p .008
dilatation ( ) in the treatment group only ( for the comparison with untreated patients with B19VP p .04 P p .017
persistence [ ]). There were significantly higher numbers of CPCs in patients with B19V persistence beforen p 5
therapy (mean  standard deviation, vs ; ) than in control subjects, which0.04%  0.05% 0.01%  0.004% P p .02
normalized after treatment ( ).P p .03
Conclusion. Thus, we present (for the first time, to our knowledge) a modulation of virally induced chronic
endothelial damage—specifically, EC apoptosis and endothelial regeneration.
Human parvovirus B19 (B19V), a erythrovirus and the
infectious agent of fifth disease in children, is often
detected in the tissues of asymptomatic individuals, and
there is ongoing debate about the functional relevance
of this finding [1–3]. On the other hand, B19V infection
is diagnosed [4] in the majority of patients with the
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clinical symptoms of atypical angina [5] and impaired
exercise capacity [6] who undergo endomyocardial bi-
opsies. Furthermore, we and other have shown that this
vasculotropic virus targets endothelial cells (ECs) with
consequent endothelial dysfunction [7–9], which in-
deed suggests a pathogenetic role for B19V. Little is
known about the mechanism of endothelial damage in
humans with persistent B19V infection. The underlying
mechanisms by which B19V might cause endothelial
damage involves the cytotoxicity of nonstructural pro-
tein 1 [10], transactivation of interleukin 6 [11] and
tumor necrosis factor a [12], and induction of apo-
ptosis (which has been demonstrated in vitro) [13–15].
Endothelial vasodilator dysfunction predicts long-
term disease progression in chronic heart failure [16]
and atherosclerosis [17]. The close relationship between
coronary artery endothelium–dependent vasomotor re-
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diated dilatation (FMD) in the brachial artery made FMD a
useful surrogate measure [18]. Vessel wall integrity is a result
of EC damage and regeneration. In vitro, EC apoptosis may
be induced by proatherosclerotic agents, whereas atheropro-
tective substances prevent EC apoptosis [19]. EC apoptosis par-
alleled early endothelial vasodilator dysfunction in an animal
model [20]. Furthermore, levels of shed apoptotic micropar-
ticles, which exert procoagulatory properties, are elevated in
acute coronary syndromes [21, 22]. Apoptotic ECs may detach
from the vessel, leading to a denudation of the vessel wall and
the need for replacement with either neighboring ECs or cir-
culating progenitor cells (CPCs) [23]. Increased EC apoptosis
will ultimately lead to either an increased replication of vessel
wall–derived mature ECs, with the consequence of premature
aging of vessel wall ECs [24], or the consumption of a pre-
sumably finite pool of CPCs [25]. EC regeneration through
CPCs plays an essential role in the maintenance of endothelial
integrity [26, 27]. Ischemia-mobilized CPCs from bone marrow
and other organs [28] home to sites of endothelial damage,
where they incorporate into newly formed vessels and partic-
ipate in reendothelialization of denuded vessels by either re-
placement [23] or paracrine actions [28].
We have previously shown that interferon beta was safe in
patients with myocardial enteroviral or adenoviral persistence
and left ventricular dysfunction and resulted in (1) elimination
of viral genomes and improved left ventricular function [29]
and in (2) reduced B19V load and improved clinical symptoms
of B19V infection [30]. Interferon beta therapy initiated after
vascular damage had occurred inhibited vascular leakage and
concurrently decreased vascular permeability in ECs, showing
a new mechanism for the anti-inflammatory action of inter-
feron beta [31]. Therefore, we tested the hypothesis that a re-
duction in endothelial damage occurs in patients with cardiac
persistence of B19V infection who have been symptomatic for
at least 0.5 years despite receiving optimal symptomatic
medications.
METHODS
Cell culture and infection with B19V. The immortalized hu-
man microvascular EC line HMEC-1 [32] was grown in me-
dium 199 (Invitrogen) supplemented with 1% penicillin-strep-
tomycin, 10 ng/mL EC growth factor (Invitrogen), 1 mg/mL
hydrocortisone, and 10% fetal calf serum. HMEC-1 cells were
seeded in 6-well cell culture dishes at cells/well. In-52.5  10
fection of HMEC-1 cells was done with prepurified B19V vi-
rions (multiplicity of infection, 100), in accordance with a
method described elsewhere [13, 33]. All experiments were per-
formed at least in triplicate.
B19V replication in mature ECs undergoing interferon beta
treatment. HMEC-1 cells were infected with B19V virions as
described elsewhere [33]. The cell supernatant was decanted,
and medium 199 containing 100–200 U/mL interferon beta
(PBL Biomedical Laboratories) was added 24 h after infection.
Cells were then harvested 96 h after infection. Total RNA was
isolated using the NucleoSpin RNA II kit (Macherey-Nagel),
in accordance with the manufacturer’s instructions. Comple-
mentary DNA of B19V RNA was obtained using Superscript
II reverse transcriptase (Invitrogen) and a B19-VP2–specific
primer (VP5; 3′-ATTTCTTTAGATAATCCCCTAGA-5′), in ac-
cordance with quantitative real-time TaqMan polymerase chain
reaction (PCR) protocol described elsewhere [7].
Cell viability and proliferation assay. HMEC-1 cells were
infected with B19V virions, and interferon beta (100–200 U/
mL) was added to the cell culture medium 24 h after infection,
as described above. Cell proliferation was analyzed using the
ViaLight Cell Proliferation kit (Cambrex Bio Science Rock-
land), in accordance with the manufacturer’s instructions.
Patients and control subjects. Inclusion criteria were age
18–75 years, documented presence of B19V genome and in-
creased endothelial activation in at least 1 endomyocardial bi-
opsy sample, onset of clinical symptoms (atypical angina, fa-
tigue, and impaired exercise capacity), and stable clinical
condition and receipt of medication for chronic heart failure
for at least 6 months. Nine consecutive patients with a pro-
longed history of cardiac symptoms (10.5 years) despite re-
ceiving symptomatic medications and with high numbers of
B19V copies (median [range], 300 [189–896] copies/mg of
DNA) in their endomyocardial biopsy samples, as measured
by real-time PCR, were allocated for interferon beta therapy
(Beneferon; Schering) and prospectively studied between Sep-
tember 2005 and November 2006 in a phase 1 study. To assess
the natural course of disease with regard to endothelial dys-
function in B19V persistence, 5 consecutive patients (median
[range] B19V copy number, 316 [214–360] copies/mg of DNA)
were recruited between April 2006 and November 2007 after
completion of the initial pilot study. In these patients, only
FMD was performed.
Exclusion criteria were diabetes; acute myocarditis; other
causes of left ventricular dysfunction; coronary heart disease;
pregnancy; antiviral, immunmodulatory, or immunosuppres-
sive therapy within the last 6 months; severe heart failure; clin-
ical or biochemical evidence of the presence of concomitant
chronic inflammatory disease; chronic renal insufficiency (cre-
atinine level, 1.4 mmol/L); inability to understand the consent
form; participation in or consent to participate in another
study; or malignant disease.
Nine patients without signs or symptoms of chronic heart
failure or coronary artery disease, diabetes, severely impaired
left ventricular function, and no more than 1 arteriosclerotic
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risk factors were defined as follows: active smoking, hypercho-
lesterinemia, positive family history (cardiovascular events in
!55-year-old male or !65-year-old female next of kin). There
were no changes in medication during the last 6 months (ie,
anti-hypertensive drugs).
All study participants provided written informed consent,
and the study was approved by the ethics committee of the
Charité, Berlin.
Physical examination, clinical assessments (including echo-
cardiography and electrocardiography), and laboratory controls
were conducted every second month to monitor for interferon
beta–associated side effects and adverse cardiac events. Assess-
ment of clinical complaints (patient diary) and heart failure
symptoms (according to the New York Heart Asssociation clas-
sification system) and the completion of a questionnaire in-
quiring about both interferon beta–associated adverse effects
(flulike symptoms, headache, and signs of inflammation) and
specific adverse cardiac symptoms (eg, angina and dyspnea)
were done at every visit.
Methods for hemodynamic, histological, and immunohis-
tological evaluations and endothelial function measurements
are given in the Appendix, which appears only in the online
version of the Journal.
Interferon beta treatment. Interferon beta therapy fol-
lowed a stepped regimen to reduce the flulike side effects typical
of the initial phase of interferon beta therapy. Subcutaneous
administration was initiated at a dose of U of interferon64  10
beta 3 times a week on alternate days and was increased to
U during the second week and to U after the6 68  10 16  10
fourth week. By the end of week 24, interferon beta therapy
was discontinued. Follow-up visits after completion of treat-
ment were prespecified to occur after 7 months (30 days;
visit 1) and after 12 months (15 days; visit 2).
Isolation of mononuclear cells and flow cytometry.
Mononuclear cells (MNCs) were isolated from peripheral blood
by means of a ficoll gradient (Histopaque 1077; Sigma). Cir-
culating mature apoptotic ECs (CMAECs) were analyzed by 4-
channel flow cytometry performed in accordance with the
methods of Mancuso et al [34] and Monstiroli et al [35] (Figure
1). After exclusion of debris and platelets, only CD45 cells
(CD45–peridinin chlorophyll protein [PerCP]; Becton Dick-
inson) were further analyzed by flow cytometry via double
staining with antibodies against the EC-specific epitopes CD146
(fluorescein isothiocyanate [FITC] conjugated; Chemicon) and
against von Willebrand factor (vWF) (goat; Calbiochem), fol-
lowed by a phycoerythrin (PE)–conjugated secondary antibody.
These CD45CD146+vWF+ cells were then assessed for apo-
ptosis with primary annexin V–allophycocyanin (APC) con-
jugates (BD Pharmingen) [36]. As an individual negative con-
trol for the CD146+vWF+ double-positive cells, a gate was set
on lymphocytes. Annexin binding was controlled by incubation
with streptavidin-coupled APC. At least 100,000 events were
counted. Measurements were done in duplicate.
CPCs were detected by flow cytometry, as described else-
where [26]. In brief, MNCs were double stained with PE-con-
jugated monoclonal antibodies against human KDR (R&D Sys-
tems) and against PerCP-conjugated CD34 (Becton Dickinson)
to depict CPCs, in accordance with the methods of Rafii [37].
Additionally, the more immature CD133+KDR+ CPCs were
stained with PE-conjugated anti–human KDR (R&D Systems)
and APC-conjugated anti–human CD133 (Becton Dickinson).
Isotype-identical antibodies served as controls (immunoglob-
ulin G [IgG] 2a–FITC and IgG1-PE; Becton Dickinson). Each
analysis included 200,000 events.
Cytokines. Levels of cytokines (stromal-derived factor 1
[SDF-1] and vascular endothelial growth factor [VEGF]) were
measured using commercially available enzyme-linked immu-
nosorbent assay kits (R&D Systems), in accordance with the
manufacturer’s instructions.
Statistical analysis. Continuous variables were tested for
normal distribution by the Kolmogorov-Smirnov test. Com-
parisons between the 2 groups were analyzed by the t test (2-
sided) for normally distributed variables. Nonnormally distrib-
uted continuous variables (FMD, CMAECs, and CD34+KDR+
CPCs) were compared by the Mann-Whitney U test. Com-
parison of categorical variables was generated by the Pearson
x2 test. Statistical significance was assumed if a null hypothesis
could be rejected at . All statistical analysis was per-P  .05
formed with SPSS software (version 14; SPSS).
RESULTS
Infection of cultured ECs. As shown in Figure 2A, there was
a statistically significant increase in replication intermediates of
B19V in HMEC-1 cells that was significantly ( ) sup-P p .008
pressed by interferon beta. B19V infection resulted in signifi-
cantly reduced cell viability and proliferation ( ) ofP p .007
HMEC-1 cells. However, after treatment with interferon beta
the viability of infected HMEC-1 cells was comparable to that
of uninfected cells, as shown in Figure 2B.
Patient characteristics. The baseline characteristics of the
23 subjects are summarized in Table 1. The 14 patients and 9
control subjects were matched for age and sex. As expected,
patients with B19V persistence had a higher incidence of angina
( for B19V with treatment; for B19V without treat-n p 7 n p 1
ment), arrhythmias ( for B19V with treatment; forn p 4 n p 1
B19V without treatment), and fatigue ( for B19V withn p 7
treatment; for B19V without treatment). The controln p 3
subjects either were healthy individuals recruited from the out-
patient clinic after exclusion of signs or symptoms of cardiac
disease ( ) or had intermittent atrio-ventricular block 2n p 6
( ) or intermittent atrial fibrillation ( ; last episode,n p 1 n p 2
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Figure 1. Flow cytometry measurement of circulating endothelial cells (ECs). Circulating cells from peripheral blood were analyzed after density
gradient separation. A, Identification of circulating mature ECs. Shown are exclusion of platelets and debris from further analysis by means of the
forward scatter (FSC) and sidescatter (SSC) view (region R1; upper left); anti–CD45–peridinin chlorophyll protein staining to identify circulating cells
other than white blood cells for further analysis (region R2; upper right); gating of CD45 cells for quantification of cells positive for the endothelial-
specific surface markers CD146–fluorescein isothiocyanate and von Willebrand factor (vWF)/goat anti-mouse–phycoerythrin (region R4; lower left); and
the negative control for setting the gate for CD146+vWF+ double-positive cells, as acquired from lymphocytes (region R3; lower right). The resulting
EC number was normalized for peripheral mononuclear cells. B, Measurement of EC apoptosis. Shown are annexin V–allophycocyanin (APC) fluorescence
of selectively gated mature ECs (left) and APC fluorescence of these cells after incubation with APC-labeled probes of the synthetic ligand streptavidin
as a negative control (right). Cells positive for annexin V were normalized for false-positive streptavidin signals.
had a mean  standard deviation (SD) number of cardiovas-
cular risk factors of , patients with B19V persistence0.7  1.1
who received treatment had , and patients with B19V1.8  1.1
persistence who did not received treatment had (Table1.8  1.3
1). There were no differences with respect to concomitant med-
ication. In endomyocardial biopsy samples, 70% of patients
had elevated levels of the endothelial activation marker inter-










940 • JID 2010:201 (15 March) • Schmidt-Lucke et al
Figure 2. A, Suppression of human parvovirus B19 (B19V) replication by interferon beta in human endothelial cells (ECs). HMEC-1 cells were infected
with serum-derived B19V virions (multiplicity of infection, 100), and interferon beta (100 U/mL) was added 24 h after infection. Cells were harvested
96 h after infection, and B19V RNA was isolated to demonstrate viral replication intermediates. B, Cell viability and proliferation of B19V-infected
human ECs undergoing interferon beta treatment. HMEC-1 cells were infected with serum-derived B19V virions (multiplicity of infection, 100). Interferon
beta (100 U/mL) was added 48 h after infection, and cells were harvested 96 h after infection. Cell proliferation was measured using the ViaLight
assay. Error bars represent standard deviations. IFN, interferon beta.
beta therapy was mostly well tolerated by all patients. All of
the patients experienced at least 1 symptom classified as mod-
erate associated with interferon; in 2 patients, symptoms were
classified as severe (leukopenia and thrombocytopenia). Inter-
feron therapy had to be interrupted in 4 patients for between
5 days and 2 weeks because of adverse events—namely, leu-
kopenia ( ), anemia ( ), and local skin reactionn p 2 n p 1
( ). Adverse effects in the 9 patients were flulike symptomsn p 1
( ), leukopenia ( ), local skin reaction ( ), head-n p 8 n p 4 n p 6
ache ( ), fever ( ), dyspnea ( ), palpitationsn p 3 n p 2 n p 2
( ), fatigue ( ), and intermittent increase in atypicaln p 2 n p 2
angina symptoms ( ). Athralgia, nausea, diarrhea, con-n p 2
juctivitis, increase in liver enzyme levels, and sore throat were
present in 1 patient each. All of the patients completed the full
course of interferon. Anti–heart failure treatment was kept con-
stant throughout the follow-up period.
The mean  SD duration of follow-up in patients with B19V
persistence who did not receive treatment was months.8  3
Clinical end points and echocardiographic measurements.
There was a significant reduction in the number of patients
with B19V persistence reporting angina pectoris after 6 months
of therapy (from 7 to 2; ), which persisted over theP p .046
actual treatment period, whereas the frequency of the symptoms
of fatigue, dyspnea, and arrhythmias remained unchanged. In
patients with B19V persistence who were not treated, symptoms
remained unchanged. There were 3 patients with B19V persis-
tence in the therapy arm and 2 patients with B19V persistence
in the no-therapy arm who experienced suppressed (!45%) left
ventricular ejection fraction (LVEF), whereas none of the con-
trol subjects had a LVEF of !45% (Table 1).
Cardiac measures were similar between groups (mean  SD
angiographic left ventricular end diastolic pressure, not avail-
able for control subjects, mm Hg for B19V with7.25  3.2
treatment, and mm Hg for B19V without treatment;17  9
mean  SD left ventricular end diastolic diameter, 48% 
for control subjects, for B19V with treatment,2% 55%  9%
and for B19V without treatment; and mean  SD51%  13%
intraventricular septal thickness, mm for control sub-10  1
jects, mm for B19V with treatment, and mm10  1 11  2
for B19V without treatment). There was a strong trend between
the 2 subgroups of patients with B19V persistence in E/A value
(mean [range], 1.1 [1.1–2.2] for control subjects, 1.33 [0.69–
1.4] for B19V with treatment, and 1.7 [1.4–1.9] for B19V with-
out treatment; ). After interferon beta therapy, thereP p .05
was no significant improvement in echocardiographic left ven-
tricular systolic or diastolic function.
Endothelial dysfunction. As illustrated in Figure 3A, highly
impaired FMD in patients with B19V persistence compared
with that in control subjects ( for B19V with treatmentP p .002
and for B19V without treatment; data not shown)P p .001
was observed in this study. Flow-mediated dilatation normal-
ized after 6 months of interferon beta therapy (mean [range],
4.7% [2.3%–5.8%] vs 12.3% [11.3%–14.6%]; ). In con-P p .04
trast, endothelium-independent dilatation was similar in con-
trol subjects and both patient groups, as depicted in Figure 3B,
and remained unchanged throughout the course of treatment.
In contrast to patients with B19V persistence who received
interferon beta therapy ( ), patients with B19V persis-P p .004
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Age, mean  SD, years 48  15 50  14 48  9
Male sex 1 (11) 3 (33) 4 (80)
Clinical characteristics
NYHA functional class
I 0 (0) 4 (44) 3 (60)
II 0 (0) 3 (33) 1 (20)
III 0 (0) 2 (22) 1 (20)
IV 0 (0) 0 (0) 0 (0)
Atypical angina 0 (0) 7 (78) 1 (20)
Arrhythmias 3 (33) 4 (44) 1 (20)
Fatigue 0 (0) 7 (78) 3 (60)
Cardiovascular risk factors
Smoking 1 (11) 3 (33) 1 (20)
Diabetes mellitus 0 (0) 0 (0) 1 (20)
Hypercholesterinemia 3 (33) 5 (55) 2 (40)
Family history 1 (11) 4 (44) 0 (0)
Arterial hypertension 3 (33) 4 (44) 3 (60)
Medication
ACE inhibitors/AT1 blockers 2 (22) 8 (89) 5 (100)
b-Blockers 3 (33) 5 (56) 5 (100)
Statins 0 (0) 3 (33) 3 (60)
Hemodynamic and echocardiographic measurements, mean  SD
LVEF echocardiography, % 60  7 54  14 46  25
Laboratory parameters, mean  SD
VEGF level, pg/mL 81  51 292  644 …
SDF-1 level, pg/mL 105  35 125  75 …
NOTE. Data are no. (%) of participants, unless otherwise indicated. There were no significant differences between the 3 groups.
ACE, angiotensin-converting enzyme; AT1, angiotensin II receptor 1; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Asssociation; SD, standard deviation; SDF-1, stromal cell derived factor 1; VEGF, vascular endothelial growth factor.
FMD. There was no correlation between systolic or diastolic
dysfunction and FMD.
CMAECs and CPCs. Figure 4A illustrates that, at baseline,
patients with B19V persistence before therapy had significantly
higher levels of CMAECs than did control subjects ( ).P p .004
EC apoptosis was significantly reduced after 6 months of in-
terferon beta therapy in patients with B19V persistence (P p
) and reached values comparable to those in control sub-.008
jects. As shown in Figure 4B, there were significantly higher
numbers of CPCs in patients with B19V persistence before
therapy ( ), compared with those in control subjects.P p .02
Similarly, the more premature subset of CPCs, character-
ized by the coexpression of CD133 and KDR, was significant-
ly increased in patients with B19V persistence (mean  SD,
vs of peripheral MNCs;0.0049%  0.003% 0.0013%  0.0009%
). Further analysis showed that only patients with aP p .007
history of angina ( ) showed a strong trend toward ele-n p 7
vated levels of CD34+KDR+ CPCs (mean  SD, 0.52% 
vs of peripheral MNCs; ). In-0.48% 0.01%  0.009% P p .059
deed, after 6 months of treatment with interferon beta the
number of CD34+KDR+ CPCs returned to normal ( ),P p .03
which persisted over the actual treatment period. None of the
cardiac medications at baseline were seen to have any effect on
EC apoptosis.
Levels of growth factors. To assess potential mobilization
of CPCs, VEGF and SDF-1 were analyzed. Plasma VEGF levels
were nonsignificantly higher in patients with B19V persistence
(mean  SD, vs pg/mL; ) and were292  644 81  51 P p .2
lowered by interferon beta therapy (mean  SD, 292  644
vs pg/mL; ). SDF-1 levels were similar in both30  21 P p .038
groups and were not altered by treatment.










Figure 3. A, Flow-mediated dilatation in 9 control subjects, in 9 patients with human parvovirus B19 (B19V) persistence before and after a 6-month
course of interferon beta therapy, and in 5 patients with B19V persistence who did not receive interferon beta therapy. Significance levels are given
for group comparisons and for changes in patients during interferon beta therapy. B, Endothelial-independent dilatation in control subjects and in
patients with B19V persistence at baseline. The horizontal line in the middle of each box indicates the median; the top and bottom borders of the
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Figure 4. Percentage of circulating mature apoptotic endothelial cells (CMAECs) (A) and of circulating CD34+KDR+ progenitor cells (CPCs) (B) among
peripheral mononuclear cells (PMNCs) in 9 control subjects and in 9 patients with human parvovirus B19 (B19V) persistence before and after a 6-
month course of interferon beta therapy. Significance levels are given for group comparisons and for changes in patients during interferon beta therapy.
The horizontal line in the middle of each box indicates the median; the top and bottom borders of the box mark the 75th and 25th percentiles,
respectively; and the whiskers above and below the box mark the range. IFN, interferon beta.
lial vasodilator dysfunction. There was an inverse correlation
between circulating mature ECs and FMD ( ;r p 0.53 P p
). The CPC-mobilizing factors SDF-1 and VEGF ( ;.02 r p .55
) were correlated with each other, but no correlationP p .02
was seen between the 2 cytokines and the 2 subsets of CPCs
or FMD.
DISCUSSION
The results of the present phase 1 study confirm and extend
previous findings of B19V-associated vascular damage. B19V
persistence is associated with endothelial dysfunction [7], atyp-
ical angina pectoris [5], and impaired exercise capacity. How-
ever, the underlying complex pathogenetic mechanisms of
B19V-induced endothelial dysfunction are unclear. To evaluate
whether immunomodulation could improve HMEC-1 cell fate
in B19V persistence, the effect of interferon beta was assessed.
The viability of HMEC-1 cells was markedly reduced after in-
fection with B19V. In vitro, interferon beta significantly reduced
viral replication in HMEC-1 cells and significantly increased
the viability of ECs, providing strong evidence that B19V-in-
duced damage of HMEC-1 cells is at least partially mediated
by direct virus-cell interaction. Clearly, the results of this study
do not provide detailed insight into the pathogenetic mecha-
nisms, which will be the aim of future studies.
To assess whether these preliminary in vitro data translate
into better endothelial function in patients with B19V infection
after interferon beta therapy, we designed a human phase 1
study to analyze different component of endothelial damage in
vivo. The inverse correlation between a significantly increased
level of circulating ECs and impaired FMD suggest that similar
pathophysiological mechanisms led to EC apoptosis and en-
dothelial dysfunction in this (albeit small) group of patients.
Given that previous studies have shown that a procoagulant
state is associated with the circulation of apoptotic micropar-
ticles [21, 22], we assume that, apart from vessel wall erosion,
circulation of increased numbers of apoptotic mature ECs
might be another component in the multifactorial pathogenesis
of endothelial dysfunction and activation. Simultaneous mea-
surements of different stages of maturation of CPCs and ma-
ture ECs allowed us to differentiate between vessel wall dam-
age and regeneration capacity. Increased levels of CD34+KDR+
CPCs—as well as the more immature subset (CD133+KDR+)—
in patients with B19V infection and angina denote a potentially
ischemia-triggered mobilization of these cells. Notably, patients
with virally induced endothelial damage and angina mobilize
CPCs, in contrast to the vascular damage evoked by classical
risk factors [38] or typical coronary heart disease [26]. Future
studies will be needed to address the functional capacity of
CPCs in B19V infection. There may be secondary mechanisms
responsible for myocardial damage in these patients.
Indeed, the results of our pilot study demonstrated that a 6-
month course of immunomodulation significantly reduced the
numbers of CMAECs and led to normalization of endothelial
dysfunction in patients with B19V infection over the actual
treatment period, pointing to a disease-modifying property of
interferon beta therapy. In contrast, we documented persistent
endothelial dysfunction in patients with B19V persistence who
did not receive treatment, hence excluding the possibility of
spontaneous improvement of endothelial damage. The under-
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further elucidated. Simultaneously, after interferon beta therapy
the clinical symptom of angina subsided in the majority of
patients with B19V persistence, and the increased numbers of
CPCs normalized. Further supporting that mobilization indeed
influenced the increased numbers of CPCs in patients with
B19V persistence was the reduction in the elevated levels of the
ischemia-induced mobilizing growth factor VEGF [28] after
interferon beta therapy. Clearly, the nature of our clinical study
does not permit us to dissect the individual components leading
to the presumably increased mobilization of CPCs in patients
with angina associated with B19V persistence.
Thus, our data provide clinical evidence for the hypothesis
that B19V contributes to ongoing vascular injury and that
chronic endothelial damage evoked by an extrinsic viral stim-
ulus can be improved by immunomodulation. However, the
present study is a phase 1 study, and even if it is unlikely that
the natural process of healing accounts for our findings after
the long period of symptoms in these patients, a randomized,
placebo-controlled phase 2 trial is warranted to confirm our
results. For ethical reasons a second biopsy was not performed
after the treatment course, so no information on the clearance
of B19V or a reduction in viral load in endomyocardial biopsy
samples after treatment can be provided. Given than the ma-
jority of our patients had a normal or only slightly reduced
ejection fraction and that there was a low incidence of con-
comitant cardiovascular risk factors as inducers of endothelial
dysfunction, we presume, but cannot prove, that B19V was the
cause of endothelial dysfunction.
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